v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting

 

(12)Segment Reporting

 

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company operates as a single reporting segment, focused on leveraging its proprietary technology platform to augment therapeutics through effective oral delivery of products and product candidates. The Company’s measure of segment profit or loss is net income (loss). The CODM is the chief executive officer (“CEO”). The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic target areas and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The review of budgeted versus actual results is used in assessing performance of the segment. All the Company’s long-lived assets are held in the United States and all the Company’s revenues are primarily related to TLANDO.

 

The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment. A reconciliation to the consolidated net loss for the three and six months ended June 30, 2026 and 2025 is included at the bottom of the table below.

 

   2026   2025   2026   2025 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2026   2025   2026   2025 
Total revenues  $190,099   $622,849   $309,496   $716,713 
Program expenses (1)                    
Lead clinical candidate  1,040,859    1,042,929    2,798,028    1,049,621 
Other research and development programs   17,155    155,415    13,894    176,388 
Non-program expenses (2)   873,833    735,511    1,861,478    1,736,128 
Personnel costs   1,042,353    1,028,142    2,204,264    2,112,907 
Stock-based compensation   58,145    65,205    123,543    136,207 
Total segment operating income (loss)   (2,842,246)   (2,404,353)   (6,691,711)   (4,494,538)
Other income (loss) (3)   219,651    198,637    397,222    423,949 
Net income (loss)  $(2,622,595)  $(2,205,716)  $(6,294,489)  $(4,070,589)

 

  (1) Includes external research and development expenses.
  (2) Includes general and administrative expenses, information technology, infrastructure, facilities, intellectual property, and legal and professional fees.
  (3) Includes interest income and income tax expense.